← All drugs
Drug · FAERS side-effect profile with label screen

Ibuprofen Sodium side effects: what 42,574 FDA adverse event reports show

Ibuprofen Sodium · 1,184 reaction terms · 162,722 drug–reaction co-reports · data 2026-09-14
Share: X Facebook Reddit Email

Drug class

Nonsteroidal Anti-inflammatory Drug

FDA label (Established Pharmacologic Class) · compare the class

Who reports

42,574 reports · 40% serious · 1,254 with death outcome · 70% female

openFDA FAERS counts, all years, deduplication not applied

Used for

Carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options before deciding to use ibuprofen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Ibuprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis.

FDA label, Indications and Usage

What it is

DESCRIPTION Ibuprofen tablets USP contain the active ingredient ibuprofen, which is (±) - 2 - ( p - isobutylphenyl) propionic acid. Ibuprofen is a white to off-white, crystalline powder with a.

FDA label, Description section

Boxed warning

Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings and Precautions ].

FDA label
How to read this page. FAERS is a spontaneous-reporting system: counts are not incidence rates and a signal is not proof of causation. Each reaction below is run through an automated screen — is the term in the FDA label (known), in the indications (the disease being treated), an administrative/coding term, or none of these (unlabeled)? That screen is mechanical text matching, not a causality assessment. The 30 hand-written Bradford Hill assessments are on the causality assessment page. Not medical advice.

Causality screen of the 40 strongest signals

Labeled — boxed warning 1Labeled (related wording) 1Likely indication confounding 1Reporting / coding artifact 10Lab value / disease marker 7Not in label — unassessed 20
What the badges mean

Strongest disproportionality signals

Flagged terms (PRR ≥ 2, χ² ≥ 4, n ≥ 10), ranked by PRR; infinite PRRs (no comparator reports) excluded. The EBGM column is a second, shrinkage-based estimate (MGPS) with its 5th percentile EB05 and the BCPNN IC025; a pair flagged by PRR alone is marked PRR-only and should be read as fragile. The strata column recomputes the PRR on serious reports only (and, for the 300 most-reported drugs, adjusted for age band), and flags pairs whose reports are unusually skewed by sex or come mostly from consumers. Each row also shows the PRR against the other drugs of the same FDA class, which removes most confounding by the condition being treated, and a calibrated p-value: on validation, known non-causes average an ROR of about 2, so significance is judged against that empirical null (✓ = p < 0.05 after calibration). 1,144 further terms are in the interactive explorer. Reaction links open the term's cross-drug page.

Show:
ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Swollen joint count3273.5
50.7–106.6ROR 73.6 · calibrated p 2e-6 ✓
61.7 EB05 45.8 · IC025 +4.4
3/3 methods agree
vs other NSAIDs: PRR 4.7 (3.3–6.8)
Not in label — unassessedserious n=32 · ♀ 100% (drug 70%) · 100% cliniciannot reported in cached trials
Grip strength2662.1
41.3–93.4ROR 62.1 · calibrated p 8e-6 ✓
53.1 EB05 38.1 · IC025 +4.1
3/3 methods agree
vs other NSAIDs: PRR 3.1 (2.1–4.6)
Not in label — unassessedserious n=26 · 100% cliniciannot reported in cached trials
Product coating issue8343.6
34.9–54.6ROR 43.7 · calibrated p 4e-5 ✓
39.8 EB05 33.1 · IC025 +4.7
3/3 methods agree
vs other NSAIDs: PRR 197.1 (121.0–321.1)
Reporting / coding artifact100% consumernot reported in cached trials
Product difficult to swallow6131.0
23.9–40.1ROR 31.0 · calibrated p 3e-4 ✓
28.9 EB05 23.3 · IC025 +4.1
3/3 methods agree
vs other NSAIDs: only this drug
Reporting / coding artifact100% consumernot reported in cached trials
Poor quality drug administered35728.3
25.4–31.4ROR 28.5 · calibrated p 4e-4 ✓
26.7 EB05 24.5 · IC025 +4.5
3/3 methods agree
vs other NSAIDs: PRR 17.7 (15.7–19.9)
Not in label — unassessedserious n=42 · 94% consumernot reported in cached trials
C-reactive protein4022.7
16.5–31.1ROR 22.7 · calibrated p 0.001 ✓
21.5 EB05 16.4 · IC025 +3.6
3/3 methods agree
vs other NSAIDs: PRR 0.5 (0.4–0.7)
Lab value / disease markerserious n=40 · ♀ 100% (drug 70%) · 100% cliniciannot reported in cached trials
Foreign body17221.8
18.7–25.4ROR 21.9 · calibrated p 0.001 ✓
20.9 EB05 18.4 · IC025 +4.1
3/3 methods agree
vs other NSAIDs: PRR 16.8 (14.1–20.0)
Not in label — unassessedserious n=28 · 100% consumerNCT00346216: 1/7,933 (0.0%) on Ibuprofen Sodium (serious AE)
Foreign body in respiratory tract5621.7
16.6–28.4ROR 21.7 · calibrated p 0.002 ✓
20.7 EB05 16.5 · IC025 +3.7
3/3 methods agree
vs other NSAIDs: PRR 46.7 (32.3–67.4)
Not in label — unassessed100% consumernot reported in cached trials
Deep vein thrombosis postoperative8020.9
16.7–26.1ROR 20.9 · calibrated p 0.002 ✓
20.0 EB05 16.6 · IC025 +3.8
3/3 methods agree
vs other NSAIDs: PRR 0.5 (0.4–0.6)
Not in label — unassessedserious n=80 · ♀ 100% (drug 70%) · 100% cliniciannot reported in cached trials
Reaction to drug excipients7517.3
13.8–21.8ROR 17.3 · calibrated p 0.004 ✓
16.7 EB05 13.7 · IC025 +3.5
3/3 methods agree
vs other NSAIDs: only this drug
Not in label — unassessed86% consumernot reported in cached trials
Drug effect delayed14616.1
13.7–19.0ROR 16.2 · calibrated p 0.005 ✓
15.6 EB05 13.6 · IC025 +3.6
3/3 methods agree
vs other NSAIDs: PRR 18.4 (15.2–22.3)
Reporting / coding artifact100% consumernot reported in cached trials
Retinitis5015.2
11.4–20.1ROR 15.2 · calibrated p 0.008 ✓
14.6 EB05 11.4 · IC025 +3.2
3/3 methods agree
vs other NSAIDs: PRR 0.7 (0.5–0.9)
Not in label — unassessedserious n=50 · ♀ 100% (drug 70%) · 100% cliniciannot reported in cached trials
Adjustment disorder with depressed mood5914.8
11.4–19.2ROR 14.8 · calibrated p 0.008 ✓
14.3 EB05 11.4 · IC025 +3.3
3/3 methods agree
vs other NSAIDs: PRR 0.4 (0.3–0.5)
Not in label — unassessedserious n=58 · ♀ 100% (drug 70%) · 100% cliniciannot reported in cached trials
Product shape issue2714.6
10.0–21.4ROR 14.6 · calibrated p 0.010 ✓
13.8 EB05 9.7 · IC025 +2.9
3/3 methods agree
vs other NSAIDs: only this drug
Reporting / coding artifact100% consumernot reported in cached trials
Product commingling3014.5
10.1–20.8ROR 14.5 · calibrated p 0.010 ✓
13.7 EB05 9.8 · IC025 +2.9
3/3 methods agree
vs other NSAIDs: PRR 54.8 (32.4–92.6)
Reporting / coding artifact100% consumernot reported in cached trials
Facet joint syndrome8713.9
11.3–17.3ROR 14.0 · calibrated p 0.010 ✓
13.5 EB05 11.2 · IC025 +3.3
3/3 methods agree
vs other NSAIDs: PRR 0.4 (0.3–0.5)
Not in label — unassessedserious n=86 · ♀ 100% (drug 70%) · 100% clinicianNCT00346216: 1/7,933 (0.0%) on Ibuprofen Sodium (serious AE)
Blood pressure diastolic abnormal7013.8
10.8–17.4ROR 13.8 · calibrated p 0.011 ✓
13.3 EB05 10.8 · IC025 +3.2
3/3 methods agree
vs other NSAIDs: PRR 1.5 (1.2–1.9)
Lab value / disease markerserious n=63 · 100% cliniciannot reported in cached trials
Blood pressure systolic abnormal6713.6
10.7–17.3ROR 13.6 · calibrated p 0.011 ✓
13.1 EB05 10.6 · IC025 +3.2
3/3 methods agree
vs other NSAIDs: PRR 1.6 (1.3–2.1)
Lab value / disease markerserious n=62 · 100% clinicianNCT00346216: 1/7,933 (0.0%) on Ibuprofen Sodium (serious AE)
Lupus vulgaris3213.6
9.6–19.3ROR 13.6 · calibrated p 0.013 ✓
12.8 EB05 9.3 · IC025 +2.9
3/3 methods agree
vs other NSAIDs: PRR 0.3 (0.2–0.5)
Not in label — unassessedserious n=32 · ♀ 100% (drug 70%) · 100% cliniciannot reported in cached trials
Dislocation of vertebra5712.9
9.9–16.8ROR 12.9 · calibrated p 0.014 ✓
12.4 EB05 9.8 · IC025 +3.1
3/3 methods agree
vs other NSAIDs: PRR 0.4 (0.3–0.5)
Not in label — unassessedserious n=57 · ♀ 100% (drug 70%) · 100% cliniciannot reported in cached trials
X-ray abnormal4412.4
9.2–16.7ROR 12.4 · calibrated p 0.017 ✓
11.8 EB05 9.0 · IC025 +2.9
3/3 methods agree
vs other NSAIDs: PRR 0.4 (0.3–0.5)
Lab value / disease markerserious n=44 · ♀ 100% (drug 70%) · 100% cliniciannot reported in cached trials
Swollen joint count increased6610.6
8.3–13.5ROR 10.6 · calibrated p 0.028 ✓
10.1 EB05 8.2 · IC025 +2.9
3/3 methods agree
vs other NSAIDs: PRR 0.3 (0.2–0.4)
Lab value / disease markerserious n=66 · ♀ 100% (drug 70%) · 100% cliniciannot reported in cached trials
Skin papilloma799.9
7.9–12.3ROR 9.9 · calibrated p 0.036 ✓
9.4 EB05 7.8 · IC025 +2.8
3/3 methods agree
vs other NSAIDs: PRR 18.1 (14.0–23.5)
Not in label — unassessedserious n=73 · ♀ 100% (drug 70%)not reported in cached trials
Porphyria acute279.8
6.7–14.3ROR 9.8 · calibrated p 0.041 ✓
8.9 EB05 6.2 · IC025 +2.4
3/3 methods agree
vs other NSAIDs: PRR 0.6 (0.4–0.8)
Not in label — unassessedserious n=27 · ♀ 100% (drug 70%) · 100% cliniciannot reported in cached trials
Peripheral venous disease779.7
7.7–12.1ROR 9.7 · calibrated p 0.038 ✓
9.2 EB05 7.6 · IC025 +2.8
3/3 methods agree
vs other NSAIDs: PRR 0.4 (0.4–0.5)
Not in label — unassessedserious n=76 · ♀ 100% (drug 70%) · 100% clinicianNCT00346216: 1/7,992 (0.0%) on Ibuprofen Sodium (serious AE)
Product used for unknown indication249.6
6.4–14.4ROR 9.6 · calibrated p 0.044 ✓
8.6 EB05 5.9 · IC025 +2.3
3/3 methods agree
vs other NSAIDs: only this drug
Reporting / coding artifact–not reported in cached trials
Rheumatic fever839.5
7.7–11.8ROR 9.5 · calibrated p 0.040 ✓
9.1 EB05 7.5 · IC025 +2.8
3/3 methods agree
vs other NSAIDs: PRR 0.3 (0.2–0.3)
Likely indication confounding
shares a disease stem with the indications wording
serious n=83 · ♀ 100% (drug 70%) · 100% cliniciannot reported in cached trials
Foreign body in throat569.2
7.1–12.0ROR 9.2 · calibrated p 0.046 ✓
8.7 EB05 6.9 · IC025 +2.6
3/3 methods agree
vs other NSAIDs: PRR 12.1 (9.1–16.3)
Not in label — unassessedserious n=55 · 100% consumernot reported in cached trials
Biliary dyskinesia319.0
6.3–12.9ROR 9.0 · calibrated p 0.052
8.2 EB05 5.9 · IC025 +2.4
3/3 methods agree
vs other NSAIDs: PRR 1.3 (0.9–1.9)
Not in label — unassessedserious n=31 · ♀ 100% (drug 70%) · 100% consumerNCT00346216: 1/7,992 (0.0%) on Ibuprofen Sodium (serious AE)
Product taste abnormal2378.8
7.8–10.0ROR 8.9 · calibrated p 0.049 ✓
8.6 EB05 7.7 · IC025 +2.9
3/3 methods agree
vs other NSAIDs: PRR 6.3 (5.5–7.2)
Reporting / coding artifactserious n=35 · 94% consumernot reported in cached trials
Pre-existing condition improved1058.3
6.9–10.1ROR 8.3 · calibrated p 0.061
8.0 EB05 6.8 · IC025 +2.7
3/3 methods agree
vs other NSAIDs: PRR 1.9 (1.5–2.3)
Not in label — unassessedserious n=17 · 83% consumernot reported in cached trials
Bone erosion578.0
6.2–10.4ROR 8.0 · calibrated p 0.070
7.6 EB05 6.0 · IC025 +2.5
3/3 methods agree
vs other NSAIDs: PRR 0.6 (0.5–0.8)
Not in label — unassessedserious n=55 · ♀ 100% (drug 70%) · 100% clinicianNCT00346216: 1/7,933 (0.0%) on Ibuprofen Sodium (serious AE)
Product size issue847.9
6.4–9.8ROR 7.9 · calibrated p 0.072
7.5 EB05 6.3 · IC025 +2.5
3/3 methods agree
vs other NSAIDs: PRR 46.9 (34.7–63.4)
Reporting / coding artifactserious n=30 · 100% consumernot reported in cached trials
C-reactive protein abnormal997.7
6.3–9.4ROR 7.7 · calibrated p 0.077
7.4 EB05 6.2 · IC025 +2.5
3/3 methods agree
vs other NSAIDs: PRR 0.3 (0.3–0.4)
Lab value / disease markerserious n=98 · ♀ 100% (drug 70%) · 100% cliniciannot reported in cached trials
Duodenal ulcer perforation1137.7
6.4–9.2ROR 7.7 · calibrated p 0.077
7.4 EB05 6.3 · IC025 +2.6
3/3 methods agree
vs other NSAIDs: PRR 0.2 (0.2–0.2)
Labeled — boxed warning
synonym match
serious PRR 11.0 · ♀ 100% (drug 70%) · 100% clinicianNCT00346216: 2/7,933 (0.0%) on Ibuprofen Sodium (serious AE)
Therapeutic product effect variable577.4
5.7–9.7ROR 7.5 · calibrated p 0.087
7.0 EB05 5.6 · IC025 +2.4
3/3 methods agree
vs other NSAIDs: PRR 112.8 (70.0–181.7)
Reporting / coding artifact100% consumernot reported in cached trials
Drug effect incomplete5377.3
6.7–7.9ROR 7.3 · calibrated p 0.086
7.1 EB05 6.6 · IC025 +2.7
3/3 methods agree
vs other NSAIDs: PRR 4.3 (4.0–4.7)
Reporting / coding artifactserious PRR 4.7 · 88% consumernot reported in cached trials
Rheumatoid factor positive847.3
5.9–9.0ROR 7.3 · calibrated p 0.092
6.9 EB05 5.8 · IC025 +2.4
3/3 methods agree
vs other NSAIDs: PRR 0.3 (0.2–0.3)
Lab value / disease markerserious n=84 · ♀ 100% (drug 70%) · 100% cliniciannot reported in cached trials
Oral discomfort2007.2
6.2–8.2ROR 7.2 · calibrated p 0.093
7.0 EB05 6.2 · IC025 +2.6
3/3 methods agree
vs other NSAIDs: PRR 3.3 (2.9–3.8)
Not in label — unassessedserious n=40 · 88% consumernot reported in cached trials

Trial evidence (ClinicalTrials.gov)

✓ Trial adverse-event data found on ClinicalTrials.gov

Largest completed trials with posted results that list Ibuprofen Sodium as a study intervention. The right-hand column of the signal table shows whether each FAERS term was also recorded in these trials, with a real denominator (7 of 40 signal terms matched).

Caveats: trial populations, doses and follow-up differ from the reporting population; AE terms are sponsor-coded and matched here by wording; absence from a trial list means the term was not reported above the sponsor's frequency threshold, not that it cannot occur.

Most frequently reported reactions

By raw co-report count, regardless of disproportionality. Common terms here are often the illness itself or generic outcomes.

ReactionReportsPRR 95% CI · ROR · χ²/pEBGM EB05 · IC025Label screenSerious-only & strataTrial cross-check
Drug ineffective (drug did not work)6,8312.6
2.5–2.6ROR 2.9 · calibrated p 0.673
2.6 EB05 2.5 · IC025 +1.3
3/3 methods agree
vs other NSAIDs: PRR 1.6 (1.6–1.7)
Reporting / coding artifactserious PRR 2.2 · 84% consumernot reported in cached trials
Fatigue (tiredness)2,7101.7
1.7–1.8ROR 1.8 · calibrated p 0.811
1.7 EB05 1.7 · IC025 +0.7
vs other NSAIDs: PRR 0.8 (0.7–0.8)
Not in label — unassessedserious PRR 2.7NCT00346216: 2/7,992 (0.0%) on Ibuprofen Sodium (serious AE)
Nausea2,7031.7
1.6–1.8ROR 1.7 · calibrated p 0.791
1.7 EB05 1.6 · IC025 +0.7
vs other NSAIDs: PRR 0.8 (0.8–0.9)
Labeled adverse reaction
exact term
serious PRR 2.6NCT00346216: 3/7,992 (0.0%) on Ibuprofen Sodium (serious AE)
Headache2,5772.0
2.0–2.1ROR 2.1 · calibrated p 0.996
2.0 EB05 2.0 · IC025 +1.0
vs other NSAIDs: PRR 0.9 (0.9–0.9)
Labeled adverse reaction
exact term
serious PRR 3.0NCT00346216: 6/7,992 (0.1%) on Ibuprofen Sodium (serious AE)
Pain2,4922.0
1.9–2.1ROR 2.1 · calibrated p 0.976
2.0 EB05 1.9 · IC025 +0.9
vs other NSAIDs: PRR 0.7 (0.7–0.8)
Labeled — boxed warning
exact term
serious PRR 2.9NCT00346216: 7/7,992 (0.1%) on Ibuprofen Sodium (serious AE)
Diarrhoea (diarrhea)1,8051.4
1.3–1.4ROR 1.4 · calibrated p 0.575
1.4 EB05 1.3 · IC025 +0.4
vs other NSAIDs: PRR 0.7 (0.7–0.7)
Labeled adverse reaction
exact term
serious PRR 1.9NCT00346216: 8/7,992 (0.1%) on Ibuprofen Sodium (serious AE)
Product use in unapproved indication1,7463.5
3.4–3.7ROR 3.6 · calibrated p 0.451
3.5 EB05 3.4 · IC025 +1.7
3/3 methods agree
vs other NSAIDs: PRR 1.9 (1.8–2.0)
Reporting / coding artifactserious PRR 2.1 · 85% consumernot reported in cached trials
Dizziness1,7421.7
1.6–1.8ROR 1.8 · calibrated p 0.803
1.7 EB05 1.7 · IC025 +0.7
vs other NSAIDs: PRR 0.8 (0.8–0.8)
Labeled adverse reaction
exact term
serious PRR 2.4NCT00346216: 5/7,992 (0.1%) on Ibuprofen Sodium (serious AE)
Arthralgia (joint pain)1,6692.0
1.9–2.1ROR 2.0 · calibrated p 0.959
2.0 EB05 1.9 · IC025 +0.9
vs other NSAIDs: PRR 0.6 (0.6–0.7)
Not in label — unassessedserious PRR 3.4NCT00346216: 33/7,992 (0.4%) on Ibuprofen Sodium (serious AE)
Off label use (used outside approved label)1,4730.8
0.8–0.9ROR 0.8 · calibrated p 0.201
0.8 EB05 0.8 · IC025 -0.3
PRR-only: not supported by EBGM or IC
vs other NSAIDs: PRR 0.6 (0.6–0.6)
Reporting / coding artifactserious PRR 1.5not reported in cached trials
Dyspnoea (shortness of breath)1,4411.3
1.2–1.3ROR 1.3 · calibrated p 0.484
1.3 EB05 1.2 · IC025 +0.2
vs other NSAIDs: PRR 0.6 (0.5–0.6)
Not in label — unassessedserious PRR 1.8NCT00346216: 24/7,992 (0.3%) on Ibuprofen Sodium (serious AE)
Vomiting1,3981.5
1.4–1.5ROR 1.5 · calibrated p 0.632
1.5 EB05 1.4 · IC025 +0.5
vs other NSAIDs: PRR 0.6 (0.6–0.6)
Labeled adverse reaction
exact term
serious PRR 2.1NCT00346216: 7/7,992 (0.1%) on Ibuprofen Sodium (serious AE)
Malaise (feeling unwell)1,3561.5
1.4–1.6ROR 1.5 · calibrated p 0.666
1.5 EB05 1.5 · IC025 +0.5
vs other NSAIDs: PRR 0.8 (0.8–0.8)
Not in label — unassessedserious PRR 2.0NCT00346216: 1/7,992 (0.0%) on Ibuprofen Sodium (serious AE)
Abdominal discomfort1,3083.9
3.7–4.1ROR 4.0 · calibrated p 0.384
3.8 EB05 3.7 · IC025 +1.9
3/3 methods agree
vs other NSAIDs: PRR 1.0 (1.0–1.1)
Not in label — unassessedserious PRR 3.8 · 76% consumerNCT00346216: 1/7,992 (0.0%) on Ibuprofen Sodium (serious AE)
Rash1,2551.4
1.4–1.5ROR 1.4 · calibrated p 0.601
1.4 EB05 1.4 · IC025 +0.4
vs other NSAIDs: PRR 0.6 (0.6–0.6)
Labeled adverse reaction
exact term
serious PRR 2.2NCT00346216: 1/8,030 (0.0%) on Ibuprofen Sodium (serious AE)

Unlabeled candidate signals

These flagged terms were not found in the FDA label text and do not match an artifact pattern. They are the pairs that would merit a structured assessment (temporality, dose-response, biological plausibility, consistency across databases, trial or cohort evidence). The screen has not done that; string-matching misses label wording, and a strong PRR can still be stimulated reporting, co-medication, or the disease itself.

✓ A hand-written Bradford Hill causality assessment exists for this drug: Ibuprofen (NSAIDs) ↔ Gastrointestinal bleeding.

Want to assess one of these properly? The runbook describes the Bradford Hill / trial-evidence workflow used on the assessment page, and handoff_top1000_signals.csv lists the strongest unassessed pairs across all drugs.

Common questions

What are the most reported side effects of Ibuprofen Sodium?

In FDA FAERS, the most frequently co-reported reaction terms for Ibuprofen Sodium are fatigue, nausea, headache, pain, diarrhoea, dizziness. These are report counts, not rates: FAERS has no denominator, reporting is voluntary and uneven, and a term can be reported because of the illness being treated rather than the drug.

Does Ibuprofen Sodium have an FDA boxed warning?

Yes. The current FDA label carries a boxed warning: Cardiovascular Thrombotic Events Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use [see Warnings and Precautions ].

Do FAERS signals prove that Ibuprofen Sodium causes these side effects?

No. A disproportionality signal (PRR, ROR) means a reaction is reported more often with this drug than with others in the database. That can reflect a real effect, but also the disease being treated, stimulated reporting after news or litigation, co-medications, or how reports are coded. Causality needs temporality, dose-response, biological plausibility, consistency across data sources and, ideally, trial or cohort evidence. This page screens each term against the FDA label and ClinicalTrials.gov results; it does not establish causation.

Sources & methods

Page generated 2026-10-14. Label and PubChem text are retrieved automatically and may lag the current label; always check the current prescribing information. OpenPV is a beta research tool of the Open Source Medicine Foundation.